Epithelial–mesenchymal transition (EMT) and its role in acquired epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) chemoresistance in non-small cell lung cancer (NSCLC)

• Published in: Cancer pathogenesis and therapy Vol. 3; no. 3; pp. 215 - 225
• Main Authors: Dela Cruz, Ma. Carmela P., Medina, Paul Mark B.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.05.2025; Elsevier
• Subjects: Epidermal growth factor receptor; Epithelial–mesenchymal transition; Non-small cell lung cancer; Resistance; Review; Tyrosine kinase inhibitors; Resistance; Epithelial–mesenchymal transition; Epidermal growth factor receptor; Tyrosine kinase inhibitors; Non-small cell lung cancer
• ISSN: 2949-7132; 2097-2563; 2949-7132
• DOI: 10.1016/j.cpt.2024.07.001

Epithelial–mesenchymal transition (EMT) is a biological process that involves the transformation of epithelial cells into cells with a mesenchymal phenotype, enhancing their migratory and invasive capabilities. EMT is crucial in embryonic development, tissue healing, and wound repair, and aids in forming diverse cell types and structures. However, aberrant EMT is involved in pathogenic processes, including fibrosis, cancer development, and progression. Recent studies show that EMT contributes to resistance to cancer treatment, including epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in non-small cell lung cancer (NSCLC). This review discusses the intricate relationship between EMT and acquired chemoresistance to EGFR-TKIs. It details evidence on how EGFR-TKIs might induce EMT and how EMT may cause EGFR-TKI resistance. Understanding these pathways is crucial for developing effective prognostic and therapeutic strategies to predict and combat acquired chemoresistance in NSCLC, advancing the field toward more targeted and personalized treatment approaches. [Display omitted] •Epithelial-mesenchymal transition (EMT) is a mechanism of chemoresistance.•Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) use can trigger EMT and EMT can consequently confers resistance.•EGFR-TKI use alters protein or miRNA expression or activity, promoting EMT.•EMT is associated with altered effector protein expression, leading to resistance.